{"id":46501,"date":"2022-07-23T06:01:38","date_gmt":"2022-07-23T04:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/"},"modified":"2022-07-23T06:01:38","modified_gmt":"2022-07-23T04:01:38","slug":"flower-one-reports-q1-22-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/","title":{"rendered":"Flower One Reports Q1-22 Financial Results"},"content":{"rendered":"<div>\n<p>LAS VEGAS&#8211;(BUSINESS WIRE)&#8211;Flower One Holdings Inc. (\u201cFlower One\u201d or the \u201cCompany\u201d) (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), the leading cannabis cultivator and producer in Nevada, today announced its financial and operating results for the first quarter ended March 31, 2022. All amounts are expressed in U.S. dollars unless indicated otherwise.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20220722005507\/en\/1261989\/5\/Flower_One_Logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20220722005507\/en\/1261989\/21\/Flower_One_Logo.jpg\"><\/a><\/p>\n<p>\n<b>First Quarter 2022 Financial and Operating Highlights:<\/b>\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe Company reported first quarter 2022 revenue of $8.9M;\n<\/li>\n<li>\nCost of flower production decreased 35% year-over-year, a result of the Company\u2019s ongoing efforts to reduce costs, without compromising flower quality;\n<\/li>\n<li>\nCompleted a $10.1M financing and implemented loan modifications to its term debt, reducing the Company\u2019s cost of capital and interest obligations.\n<\/li>\n<\/ul>\n<p>\n\u201cDespite ongoing market pressures, our team has continued to drive our business forward making significant progress on cost savings, debt reduction and our overall turnaround plan,\u201d said Kellen O\u2019Keefe, Flower One\u2019s President &amp; CEO. \u201cOur commitment to producing quality cannabis at scale is at the heart of everything we do as an organization and we are currently producing the best quality flower in the Company\u2019s history, while simultaneously reducing our cost of production.\u201d\n<\/p>\n<p>\n<b>First Quarter 2022 Financial Results:<\/b>\n<\/p>\n<p>\n<b><span class=\"bwuline\">Revenues<\/span><\/b>\n<\/p>\n<p>\nFor the three-month period ended March 31, 2022, the Company reported revenue of $8.9M, representing approximately 10-15% of the state\u2019s wholesale market. Nevada\u2019s cannabis market continues to be harshly affected by the ongoing impact of the pandemic, and a thriving black market, which has resulted in price compression and decreased statewide cannabis sales. While tourism has continued to slowly rebound to pre-pandemic levels, visitor counts still remain far below expectations as a direct result of the reduction in conferences, corporate, and international travel. Nevada\u2019s first quarter 2022 retail cannabis sales decreased by over 21%, as compared to first quarter 2021.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Expenses<\/span><\/b>\n<\/p>\n<p>\nCost of sales for the first quarter of 2022 was $5M, compared to $5M from the same period in 2021. The decrease in gross margin is a direct result of wholesale price compression driven by topline market softening and increased supply. The Company has implemented cost saving initiatives, including reducing the cost of flower production by 35%. These cost saving initiatives have significantly minimized the decrease in gross margin.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Profitability Measures<\/span><\/b>\n<\/p>\n<p>\nFirst quarter 2022 gross profit before fair value adjustments was $3.9M, compared to $8.9M from the same period of the prior year. The decrease in gross profit is directly attributable to the decline in topline revenue, as well as the fair value adjustments recorded on biological asset transformation.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwtopsingle bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwpadl0 bwnowrap bwalignc\" colspan=\"7\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Three months ended March 31,<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>2022<\/b>\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwalignc\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb bwalignc\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>2021<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<i>(As Restated)<\/i>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRevenue\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n8,949,249\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n$\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n13,877,853\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCost of sales\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n5,031,423\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n4,969,319\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGross profit before fair value adjustments\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n3,917,826\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n8,908,534\n<\/p>\n<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwpadl2\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nGross margin before impact of biological assets\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n44\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n%\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignr bwcellpmargin\">\n64\n<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadl0 bwpadr0 bwvertalignb\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n%\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nFor the quarter, the Company recorded a net loss of $10.2M, compared to a net loss of $15.8M for the same period of the prior year. The Company\u2019s finance costs were reduced by approximately 40%, including a 37% decrease to its interest expense year-over-year.\n<\/p>\n<p>\n<b><span class=\"bwuline\">Balance Sheet<\/span><\/b>\n<\/p>\n<p>\nAs of March 31, 2022, the Company had cash and cash equivalents of $4.7M, compared with $4.9 as of March 31, 2021. Our overall liability balance has decreased by $28.2M year-over-year.\n<\/p>\n<p>\n\u201cAs a Company, we have implemented a variety of measures across the organization that reduced our overall costs, in spite of a very challenging global economic environment,\u201d said Araxie Grant, Flower One\u2019s CFO. \u201cControlling our costs during these times is a testament to our team\u2019s financial discipline, and represents significant progress towards achieving positive cash flow. Our finance department\u2019s ability to provide precise and insightful data continues to improve, enabling us to make better strategic decisions and create shareholder value.\u201d\n<\/p>\n<p>\nFlower One\u2019s first quarter 2022 financial statements and management\u2019s discussion and analysis will be issued and filed on SEDAR at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sedar.com&amp;esheet=52789317&amp;newsitemid=20220722005507&amp;lan=en-US&amp;anchor=www.sedar.com&amp;index=1&amp;md5=96c1ee8a4d59f5b8c1e1239c60cfc4d0\" rel=\"nofollow noopener\" shape=\"rect\">www.sedar.com<\/a> on July 22, 2022 and will also be available on Flower One\u2019s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.flowerone.com%2Finvestors%2Ffinancial-reports&amp;esheet=52789317&amp;newsitemid=20220722005507&amp;lan=en-US&amp;anchor=www.flowerone.com%2Finvestors%2Ffinancial-reports&amp;index=2&amp;md5=32672ea5fd7bddfc60c6f5bea0709efa\" rel=\"nofollow noopener\" shape=\"rect\">www.flowerone.com\/investors\/financial-reports<\/a>.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"3\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Conference Call Details:\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>\u00a0<\/b>\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>\u00a0<\/b>\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nDate:\u00a0\u00a0\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTuesday, July 26, 2022\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTime:\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n10:00 a.m. ET\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCall:\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n1-877-407-0789 (Canada and US)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n1-201-689-8562 (International)\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nConference ID:\u00a0\u00a0\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwalignl\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n13731617\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nWebcast:\n<\/p>\n<\/td>\n<td colspan=\"1\" rowspan=\"1\">\u00a0<\/td>\n<td class=\"bwvertalignt bwpadl0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nA live webcast will be available on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fflowerone.com%2Finvestors%2Ffinancial-reports%2F&amp;esheet=52789317&amp;newsitemid=20220722005507&amp;lan=en-US&amp;anchor=Flower+One%26%238217%3Bs+website&amp;index=3&amp;md5=45bf1b7f3522a672f836bae09365396b\" rel=\"nofollow noopener\" shape=\"rect\">Flower One\u2019s website<\/a> or <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fviavid.webcasts.com%2Fstarthere.jsp%3Fei%3D1560156%26tp_key%3D458bb75d7c&amp;esheet=52789317&amp;newsitemid=20220722005507&amp;lan=en-US&amp;anchor=ViaVid&amp;index=4&amp;md5=7b9f6476ab12705dd237c7dad5e353d8\" rel=\"nofollow noopener\" shape=\"rect\">ViaVid<\/a>.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\nAll interested parties are invited to participate. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast.\n<\/p>\n<p>\nFor those unable to join the live webcast, a telephone replay will be available until 11:59 p.m. ET on Tuesday, August 2, 2022, and can be accessed by dialing 1-844-512-2921 (toll free) or 1-412-317-6671 (international) and provide pin number 13731617. Additionally, to access the archived webcast, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fflowerone.com%2Finvestors%2Ffinancial-reports%2F&amp;esheet=52789317&amp;newsitemid=20220722005507&amp;lan=en-US&amp;anchor=Flower+One%26%238217%3Bs+website&amp;index=5&amp;md5=49fec45792ca0f08d70594859c242364\" rel=\"nofollow noopener\" shape=\"rect\">Flower One\u2019s website<\/a>.\n<\/p>\n<p>\n<b>Restatement of 2021 Interim Financial Information<\/b>\n<\/p>\n<p>\nThe Company previously announced that, on the recommendation of the Audit Committee of the Company\u2019s Board of Directors and after consultation with MNP LLP, the Company\u2019s independent registered public accounting firm, that Flower One\u2019s previously issued unaudited interim financial statements for each of the first, second and third quarters of 2021 prepared in accordance with International Financial Reporting Standards as filed on SEDAR would be restated and should no longer be relied upon.\n<\/p>\n<p>\nAs a result, the Company has made both material and immaterial restatements to (1) cash and cash equivalents, (2) current and long term prepaids and deposits, (3) the carrying value of cannabis and oil-based cannabis inventory, and related cost of sales, (4) the valuation of biological assets and related fair value adjustments, (5) property, plant and equipment, loss on disposal of assets and related depreciation, (6) trade payables, accrued liabilities and construction payables, (7) valuation methodology for convertible debentures and warrants, and related derivative liability and fair value loss on derivatives, (8) the classification of current and non-current equipment financing and term debt balances, (9) general and administrative expenses, (10) stock based compensation expense for Restricted Share Units (\u201cRSUs\u201d) granted in 2021, (11) loss on debt modification or extinguishment related to debt modifications, (12) related party transaction disclosures, and (13) finance expenses, including interest, accretion and transaction costs.\n<\/p>\n<p>\nThe Company has made restatements retrospectively to the comparative period as at and for the three-month period ended March 31, 2021. The condensed consolidated interim financial statements for the periods as at and ended between March 31, 2021 and September 30, 2021 were not adjusted and refiled at the time of discovery of the need for restatement, rather the comparative period as at and for the three month period ended March 31, 2021, has been corrected in the unaudited condensed interim consolidated financial statements as at the three-month period ended March 31, 2022. The periods as at and ending June 31, 2021 and September 30, 2021, will be corrected within the filing of the condensed consolidated interim financial statement as at and for the three month period ended June 31, 2022.\n<\/p>\n<p>\n<b>About Flower One Holdings Inc.<\/b>\n<\/p>\n<p>\nFlower One is the largest cannabis cultivator, producer, and full-service brand fulfillment partner in the state of Nevada. By combining more than 20 years of greenhouse operational excellence with best-in-class cannabis operators, Flower One offers consistent, reliable, and scalable fulfillment to a growing number of industry-leading cannabis brands (Cookies, Kiva, Old Pal, Heavy Hitters, Lift Ticket\u2019s, The Clear, HUXTON, and Flower One\u2019s leading in-house brand, NLVO, and more). Flower One currently produces a wide range of products from flower, full-spectrum oils, and distillates to finished consumer packaged goods, including a variety of: pre-rolls, concentrates, edibles, topicals, and more for top-performing brands in cannabis. Flower One\u2019s Nevada footprint includes the Company\u2019s flagship facility, a 400,000 square-foot high-tech greenhouse and 55,000 square-foot production facility, as well as a second site with a 25,000 square-foot indoor cultivation facility and commercial kitchen. Flower One has built an industry-leading team focused on making high-quality cannabis accessible to all.\n<\/p>\n<p>\nThe Company\u2019s common shares are traded on the Canadian Securities Exchange under the Company\u2019s symbol \u201cFONE\u201d, in the United States on the OTCQX Best Market under the symbol \u201cFLOOF\u201d and on the Frankfurt Stock Exchange under the symbol \u201cF11\u201d. For more information, visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fflowerone.com&amp;esheet=52789317&amp;newsitemid=20220722005507&amp;lan=en-US&amp;anchor=https%3A%2F%2Fflowerone.com&amp;index=6&amp;md5=635d6e478c46df8ddb36278dfaa295c9\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/flowerone.com<\/a>.\n<\/p>\n<p>\n<b>Cautionary Note Regarding Forward-Looking Information<\/b>\n<\/p>\n<p>\nStatements in this press release that are not statements of historical or current fact constitute \u201cforward-looking information\u201d within the meaning of Canadian securities laws and \u201cforward-looking statements\u201d within the meaning of United States securities laws (collectively, \u201cforward-looking statements\u201d). Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from historical results or from any future actual results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms \u201cbelieves,\u201d \u201cbelief,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201canticipates,\u201d \u201cpotential,\u201d \u201cshould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cplans,\u201d \u201ccontinue\u201d or other similar expressions to be uncertain and forward-looking.\n<\/p>\n<p>\nForward-looking statements may include, without limitation, statements relating to the Company\u2019s position as a leader in the Nevada cannabis market and anticipated sales and record revenue; the Company\u2019s leadership as a cannabis cultivator, producer, innovator and full-service brand fulfillment partner; the production of a wide range of products for the nation\u2019s top-performing brands; the Company continuing to see the positive impacts of the cost-savings measures; the quantum of adjustments for the restated 2021 financial information; and the Company\u2019s expectation that the Q2-21 and Q3-21 Statements will be restated.\n<\/p>\n<p>\nThe forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement, the \u201cCautionary Statement regarding Forward-Looking Information\u201d section contained the Company\u2019s management\u2019s discussion and analysis for the three and twelve months ended December 31, 2021 (the \u201cMD&amp;A\u201d). All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Company\u2019s public securities filings with the Canadian securities commissions, including the Company\u2019s MD&amp;A. Although Flower One has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those contained in the forward-looking statements, there can be other factors that cause results, performance or achievements not to be as anticipated, estimated or intended.\n<\/p>\n<p>\nAlthough the Company believes that any forward-looking information and statements herein are reasonable, in light of the use of assumptions and the significant risks and uncertainties inherent in such information and statements, there can be no assurance that any such forward-looking information and statements will prove to be accurate, and accordingly readers are advised to rely on their own evaluation of such risks and uncertainties and should not place undue reliance upon such forward-looking information and statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this press release are made as of the date of this release. Flower One disclaims and does not undertake any intention or obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.\n<\/p>\n<p>\nNEITHER THE CANADIAN SECURITIES EXCHANGE NOR THEIR REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nFlower One Investor Relations<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;a&#x69;&#108;&#x74;&#x6f;:&#x69;&#114;&#x40;&#x66;l&#x6f;&#119;&#x65;&#x72;o&#x6e;&#101;&#x2e;&#x63;o&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x69;&#114;&#64;f&#x6c;&#x6f;&#119;e&#x72;&#x6f;&#110;e&#46;&#x63;&#111;&#109;<\/a>\n<\/p>\n<p>\nKellen O\u2019Keefe, President &amp; CEO<br \/>\n<br \/>702.660.7775\n<\/p>\n<p>\nFlower One Media<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#111;&#x3a;&#109;&#x65;d&#x69;a&#64;&#x66;&#108;&#x6f;w&#x65;&#x72;&#111;&#x6e;e&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#x6d;&#101;d&#x69;&#97;&#64;&#x66;&#108;o&#x77;&#x65;&#114;&#x6f;&#x6e;&#101;&#46;&#x63;&#111;m<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>LAS VEGAS&#8211;(BUSINESS WIRE)&#8211;Flower One Holdings Inc. (\u201cFlower One\u201d or the \u201cCompany\u201d) (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), the leading cannabis cultivator and producer in Nevada, today announced its financial and operating results for the first quarter ended March 31, 2022. All amounts are expressed in U.S. dollars unless indicated otherwise. First Quarter 2022 Financial and &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-46501","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Flower One Reports Q1-22 Financial Results - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Flower One Reports Q1-22 Financial Results - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LAS VEGAS&#8211;(BUSINESS WIRE)&#8211;Flower One Holdings Inc. (\u201cFlower One\u201d or the \u201cCompany\u201d) (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), the leading cannabis cultivator and producer in Nevada, today announced its financial and operating results for the first quarter ended March 31, 2022. All amounts are expressed in U.S. dollars unless indicated otherwise. First Quarter 2022 Financial and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-23T04:01:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220722005507\/en\/1261989\/21\/Flower_One_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Flower One Reports Q1-22 Financial Results\",\"datePublished\":\"2022-07-23T04:01:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/\"},\"wordCount\":1838,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220722005507\\\/en\\\/1261989\\\/21\\\/Flower_One_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/\",\"name\":\"Flower One Reports Q1-22 Financial Results - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220722005507\\\/en\\\/1261989\\\/21\\\/Flower_One_Logo.jpg\",\"datePublished\":\"2022-07-23T04:01:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220722005507\\\/en\\\/1261989\\\/21\\\/Flower_One_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220722005507\\\/en\\\/1261989\\\/21\\\/Flower_One_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/flower-one-reports-q1-22-financial-results\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Flower One Reports Q1-22 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Flower One Reports Q1-22 Financial Results - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Flower One Reports Q1-22 Financial Results - Pharma Trend","og_description":"LAS VEGAS&#8211;(BUSINESS WIRE)&#8211;Flower One Holdings Inc. (\u201cFlower One\u201d or the \u201cCompany\u201d) (CSE: FONE) (OTCQX: FLOOF) (FSE: F11), the leading cannabis cultivator and producer in Nevada, today announced its financial and operating results for the first quarter ended March 31, 2022. All amounts are expressed in U.S. dollars unless indicated otherwise. First Quarter 2022 Financial and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/","og_site_name":"Pharma Trend","article_published_time":"2022-07-23T04:01:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220722005507\/en\/1261989\/21\/Flower_One_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Flower One Reports Q1-22 Financial Results","datePublished":"2022-07-23T04:01:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/"},"wordCount":1838,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220722005507\/en\/1261989\/21\/Flower_One_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/","url":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/","name":"Flower One Reports Q1-22 Financial Results - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220722005507\/en\/1261989\/21\/Flower_One_Logo.jpg","datePublished":"2022-07-23T04:01:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220722005507\/en\/1261989\/21\/Flower_One_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220722005507\/en\/1261989\/21\/Flower_One_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/flower-one-reports-q1-22-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Flower One Reports Q1-22 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46501","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=46501"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/46501\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=46501"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=46501"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=46501"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}